A phase IIa trial of durvalumab in combination with tumor-infiltrating lymphocytes in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
Phase of Trial: Phase II
Latest Information Update: 27 Jun 2017
At a glance
- Drugs Durvalumab (Primary) ; LN 145 (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Iovance Biotherapeutics
- 27 Jun 2017 According to an Iovance Biotherapeutics media release, Lion Biotechnologies has changed its name to Iovance Biotherapeutics.
- 01 Jun 2017 According to a Lion Biotechnologies, first patient has been dosed.
- 01 May 2017 Status changed from planning to recruiting, according to a Lion Biotechnologies media release.